• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aptevo Therapeutics Inc.

    7/12/24 4:30:45 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email
    S-8 1 apvo-2024-s8_-_sip_incre.htm S-8 S-8

     

    As filed with the U.S. Securities and Exchange Commission on July 12, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Aptevo Therapeutics Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

     

    81-1567056

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer Identification No.)

     

    2401 4th Avenue, Suite 1050

    Seattle, WA 98121

    (Address of principal executive offices) (Zip code)

     

     

    Aptevo Therapeutics Inc. Second Amended and Restated 2018 Stock Incentive Plan

    (Full title of the plan)

     

     

    SoYoung Kwon

    Senior Vice President and General Counsel

    Aptevo Therapeutics Inc.

    2401 4th Avenue, Suite 1050

    Seattle, WA 98121

    (206) 838-0500

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.

    Large accelerated filer

    

     

    Accelerated filer

    

    Non‑accelerated filer

    

     

    Smaller reporting company

    

     

     

     

    Emerging growth company

    

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     


     

    EXPLANATORY NOTE

    On August 9, 2018, Aptevo Therapeutics Inc. (the "Company" or the "Registrant") filed a registration statement on Form S-8 (File No. 333-226717) (the "Initial Registration Statement") with the Securities and Exchange Commission (the "Commission") to register 4,749 (adjusted for 1-for-14 reverse stock split effective March 26, 2020, and 1-for-44 reverse stock split effective March 5, 2024) shares of the Company's common stock, par value $0.001 per share ("Common Stock"), for issuance or sale pursuant to the Aptevo Therapeutics Inc. 2018 Stock Incentive Plan. On June 7, 2022, the Company filed a registration statement on Form S-8 (File No. 333-365468) with the Commission to register 11,363 shares (adjusted for 1-for-44 reverse stock split effective March 5, 2024) of the Company's Common Stock for issuance or sale pursuant to the Company's Amended and Restated 2018 Stock Incentive Plan (the "Current Plan").

     

    The Company’s board of directors adopted, subject to approval by stockholders, the Second Amended and Restated 2018 Stock Incentive Plan (the “Second Amended Plan”), which the Company’s stockholders approved at the Company’s 2024 annual meeting of stockholders held on June 7, 2024. The Second Amended Plan made the following amendments, among others, to the Current Plan:

    •
    Increased authorized pool of shares. The Second Amended Plan increased the number of shares authorized for issuance under the Current Plan by 165,000 shares of Common Stock.
    •
    No liberal share recycling of options or stock appreciation rights. Shares underlying options and stock appreciation rights issued under the Second Amended Plan are not recycled into the share pool under the Second Amended Plan if they are withheld in payment of the exercise price of the award or to satisfy tax withholding obligations in respect of such awards.
    •
    Restrictions on Dividends and Dividend Equivalents. The Second Amended Plan prohibits participants from receiving current dividends or dividend equivalents that are paid before the underlying award vests and is paid.
    •
    Enhanced clawback provisions. The Second Amended Plan includes recoupment, or “clawback” provision set forth in the Current Plan, under which any award agreement may provide for the cancellation or forfeiture of an award or the forfeiture and repayment to the Company of any gain related to an award, or other provisions intended to have a similar effect, upon such terms and conditions as may be determined by the Committee (as defined below) in accordance with any Company clawback policy (or successor policy) or otherwise, including as required by the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or other applicable law, regulation or stock exchange listing requirement. This clawback provision also provides that participants in the Second Amended Plan agree to and acknowledge that they are obligated to cooperate with, and provide any and all assistance necessary to, the Company to recover or recoup any award or amount paid under the Second Amended Plan that becomes subject to clawback pursuant to any applicable law, government regulation, stock exchange listing requirement or policy of the Company, including, but not limited to, submitting documentation necessary to recover or recoup any such award.
    •
    New Term. The Second Amended Plan also provides that awards may be granted pursuant to the Second Amended Plan until April 15, 2034.

    The Company is filing this registration statement on Form S-8 (this “Registration Statement”) solely for the purpose of registering the 165,000 additional shares of Common Stock authorized for issuance under the Second Amended Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also includes an indeterminate number of additional shares of Common Stock that may become issuable under the Second Amended Plan by reason of anti-dilution and other adjustments.

    Pursuant to General Instruction E of Form S-8, this Registration Statement hereby incorporates by reference the contents of the previously filed registration statements on Form S-8 filed with the Commission on August 8, 2018 (File No. 333-226717) and on June 7, 2022 (File No. 333-365468), and the information required by Part II is omitted, except as supplemented by the information set forth below.

     

     


     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation Of Certain Documents By Reference

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    (a) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on March 5, 2024, including the portions of the Company’s Definitive Proxy Statement on Schedule 14A filed on April 23, 2024, that are incorporated by reference in the Annual Report on Form 10-K;
     

    (b) the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 8, 2024;

     

    (c) the Company’s Current Reports on Form 8-K filed on February 6, 2024, March 5, 2024, March 7, 2024, April 15, 2024, June 10, 2024, July 1, 2024 and July 1, 2024.

     

    (d) the description of the Registrant’s Common Stock which is contained in Exhibit 4.8 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023; and

    (e) all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     


     

    Item 8. Exhibits

     

     

     

    Exhibit

    Number

    Description

     

     

    3.1(1)

    Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc.

     

     

     

    3.2(2)

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics Inc.

     

     

     

    3.3(3)

     

    Certificate of Designation of Series A Junior Participating Preferred Stock of Aptevo Therapeutics Inc.

     

     

     

    3.4(4)

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of Aptevo Therapeutics, Inc.

     

     

    3.5(5)

    Amended and Restated Bylaws of Aptevo Therapeutics Inc.

     

     

    4.1(6)

    Form of Common Stock Certificate

     

     

    5.1

    Opinion of Paul Hastings LLP, legal counsel of Registrant

     

     

    23.1

    Consent of Moss Adams LLP

     

     

    23.2

    Consent of Paul Hastings LLP, legal counsel of Registrant (included in Exhibit 5.1)

     

     

    24.1

    Power of Attorney (see signature page hereto).

     

     

    99.1(7)

    Second Amended and Restated 2018 Stock Incentive Plan

     

     

     

    107

     

    Filing Fee Table

     

    (1)

    Previously filed as Exhibit 3.1 of the Registrant’s Form 8-K filed on August 2, 2016, File No. 001-37746 and incorporated herein by reference.

    (2)

    Previously filed as Exhibit 3.1 of the Registrant’s Form 8-K filed on March 27, 2020, File No. 001-37746 and incorporated herein by reference.

    (3)

    Previously filed as Exhibit 3.1 of the Registrant’s Form 8-K filed on November 9, 2020, File No. 001-37746 and incorporated herein by reference.

    (4)

    Previously filed as Exhibit 3.1 of the Registrant’s Form 8-K filed on March 5, 2024, File No. 001-37746 and incorporated herein by reference.

    (5)

    Previously filed as Exhibit 3.2 of the Registrant’s Form 8-K filed on August 2, 2016, File No. 001-37746 and incorporated herein by reference.

    (6)

    Previously filed as Exhibit 4.1 of the Registrant’s Form 10 filed on June 29, 2016, File No. 001-37746 and incorporated herein by reference.

    (7)

    Previously filed as Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 23, 2024, File No. 001-37746 and incorporated herein by reference.

     

     

     

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, State of Washington, on this 12th day of July, 2024.

     

    Aptevo Therapeutics Inc.

     

     

     

     

    By:

    /s/ Marvin L. White

    Marvin L. White
    President and Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Marvin L. White, Daphne Taylor, and SoYoung Kwon and each of them, each with full power to act without the other, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any amendments to this registration statement, and to sign any registration statement for the same offering covered by this registration statement, including post-effective amendments or registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming that each of said such attorneys-in-fact and agents or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities on the 12th day of July, 2024..

     

     

    Signatures

    Title

    /s/Marvin L. White

     President, Chief Executive Officer and Director

    Marvin L. White

     (Principal Executive Officer)

    /s Daphne Taylor

    Senior Vice President and Chief Financial Officer

    Daphne Taylor

    (Principal Financial and Accounting Officer)

    /s/John E. Niederhuber, M.D.

    Chairman of the Board of Directors

    John E. Niederhuber, M.D.

    /s/Daniel J. Abdun-Nabi

     Director

    Daniel J. Abdun-Nabi

    /s/Grady Grant, III

     Director

    Grady Grant, III

    /s/Zsolt Harsanyi, Ph. D.

     Director

    Zsolt Harsanyi, Ph. D.

    /s/Barbara Lopez Kunz

     Director

    Barbara Lopez Kunz

     

     

     


    Get the next $APVO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    SEC Filings

    View All

    Aptevo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

    2/3/26 8:15:25 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Aptevo Therapeutics Inc.

    EFFECT - Aptevo Therapeutics Inc. (0001671584) (Filer)

    2/2/26 12:15:32 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B4 filed by Aptevo Therapeutics Inc.

    424B4 - Aptevo Therapeutics Inc. (0001671584) (Filer)

    1/30/26 5:02:47 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

    Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

    5/28/21 8:33:45 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

    Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

    1/15/25 8:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

    SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

    12/12/24 12:50:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

    Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

    12/12/24 9:00:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Bank Of America Corp /De/

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    10/3/25 2:19:07 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bank Of America Corp /De/ claimed ownership of 27 shares (SEC Form 3)

    3 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    10/3/25 1:59:55 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

    NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

    11/2/21 9:00:00 AM ET
    $AMGN
    $APVO
    $BCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Specialty Insurers

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

    SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/14/24 3:45:38 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    11/8/24 2:57:35 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aptevo Therapeutics Inc.

    SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

    2/14/24 3:24:02 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care